Package Leaflet: Information for the User
Cefazoline Sala 1 g Powder for Solution for Injection EFG
Cefazoline
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the Package Leaflet:
Cefazoline is an antibiotic belonging to the group of cephalosporins.
Antibiotics are used to treat bacterial infections and are not effective against viral infections such as flu or common cold.
It is important that you follow the instructions regarding dosage, administration interval, and treatment duration as indicated by your doctor.
Do not store or reuse this medication. If you have any leftover antibiotic after completing treatment, return it to the pharmacy for proper disposal. Do not dispose of medications through the drain or in the trash.
This medication is used for the treatment of the following bacterial infections caused by susceptible pathogens localized in:
Do not use Cefazoline Sala
Warnings and precautions
Be careful with Cefazoline Sala
On rare occasions, blood coagulation disorders may occur during treatment with cefazoline. Additionally, changes in blood coagulation may occur in patients with diseases that can cause or worsen bleeding, such as hemophilia or stomach or intestinal ulcers. In these cases, your blood coagulation will be monitored.
Other medications and Cefazoline Sala
Tell your doctor or pharmacist if you are using or have recently used any other medications, including those obtained without a prescription.
Cefazoline should not be administered with:
Pregnancy and breastfeeding
In case of pregnancy or breastfeeding, your doctor will decide whether to use this medication. Consult your doctor or pharmacist before taking any medication.
Driving and using machines
Cefazoline generally does not affect the ability to drive vehicles or operate machinery.
Cefazoline Sala contains sodium
Patients on low-sodium diets should note that this medication contains 51 mg (2.2 mmol) of sodium per gram of cefazoline.
Follow your doctor's instructions for administering this medication exactly. If in doubt, consult your doctor or pharmacist again.
Your doctor will indicate the appropriate dose and determine the duration of your treatment; do not stop it prematurely or prolong it.
Recommended dose
Adults and children over 12 years: for mild infections, 500 mg every 8 hours; for moderate to severe infections, 500 mg to 1 g every 6 or 8 hours; for more severe infections, 1 g to 1.5 g every 6 hours.
Children (under 12 years and over 1 year): a total daily dose of 25 to 50 mg per kg of body weight, divided into three or four equal doses, is effective in most mild to moderate infections. The total daily dose should not exceed 100 mg/kg, even in severe infections.
Prophylactic treatment
Patients with renal and/or hepatic insufficiency
A dose reduction may be necessary if you have any renal or hepatic impairment. In such cases, inform your doctor so that they can adjust the dose accordingly.
If you use more Cefazoline Sala than you should
In case of accidental overdose, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount taken. Bring the package leaflet with you.
If you forget to use Cefazoline Sala
Do not take a double dose to make up for forgotten doses.
If you stop treatment with Cefazoline Sala
Do not stop treatment before completing it, as the desired effect will not be achieved. It is very important to treat infections for the recommended time; otherwise, they may worsen.
If you have any further questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause the following side effects, although not everybody gets them.
The incidence of adverse reactions associated with Cefazoline Sala treatment is classified as follows:
Severe allergic reactions(very rare, may affect up to 1 in 10,000 people).
If you have a severe allergic reaction, inform your doctor immediately.
Possible symptoms include:
Other possible side effects
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines (https://www.notificaram.es). By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the packaging. The expiration date is the last day of the month indicated.
Store in the outer packaging to protect from light.
The reconstituted solution is stable for 8 hours at a temperature not exceeding 25°C and for 24 hours if stored in the refrigerator (2-8°C).
Do not use this medication if you observe visible signs of deterioration.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and any unused medication in the pharmacy's SIGRE collection point. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Cefazoline Sala
The active ingredient is cefazoline. Each vial contains 1 g of cefazoline (D.O.E.) (as cefazoline sodium).
Appearance of the product and pack contents
Cefazoline Sala 1 g Powder for Solution for Injection EFG is presented in a glass vial.
Each pack contains 1 vial, and the clinical pack contains 100 vials.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Laboratorio Reig Jofre, S.A.
Gran Capitán, 10 – 08970
Sant Joan Despí (Barcelona)
Spain
Manufacturer:
Laboratorio Reig Jofre, S.A.
C/Jarama 11, Polígono industrial-45007
Toledo-Spain
Date of the last revision of this leaflet: December 2024
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
---------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals
Instructions for the correct administration of the product
Intravenous administration:cefazoline can be administered by direct intravenous injection or by continuous or intermittent infusion (never dissolved in lidocaine).
Sodium chloride 0.9%
Glucose 5% or 10%
Glucose 5% in Ringer lactate
Sodium chloride 0.9% and glucose 5%
Sodium chloride 0.45% and glucose 5%
Ringer lactate
Fructose 5% or 10% in water for injection
500 mg or 1 g reconstituted: diluted in 10 ml of water for injection.
2 g reconstituted: diluted in a minimum of 20 ml of water for injection.
The solution is injected slowly over 3 to 5 minutes (it should not be administered in less than three minutes)